The relevance of this issue is underscored when one considers that IFN-associated adverse effects can result in the discontinuation of treatment.4 A recent series has reported the discontinuation of IFN in 17% of HCV-infected patients, mainly due to cardiovascular complications.5 Apart from one report from a large population, much lower frequencies of cardiovascular complications of IFN [7 out of 11241 (0.06%)] in patients with chronic hepatitis have been reported.6 Here, IFNA1 is linked to chronic hepatitis.